What if potential patient candidates could be identified in real time from the point of diagnosis?
Precision for Medicine (PFM) recently entered a strategic partnership with digital healthcare innovator, Deep Lens, to significantly enhance clinical trial recruitment and enrollment.
Using artificial intelligence (AI) for targeted patient identification, Deep Lens accelerates oncology clinical trial recruitment. Through their partnership, Precision’s internal teams and sponsors can access Deep Lens’ Real Time Feasibility service. This service leverages the proprietary cloud-based software solution, VIPER, and its network of research-capable community oncology sites to combine electronic medical records (EMR), as well as lab and genomic data, to gain insights about specific patient populations.
In this article, we will provide detail on the following topics:
Through the Deep Lens Unity Network of community-based oncology practices, new patient data is being ingested and updated on a continuous, real-time basis. Deep Lens’ VIPER uses advanced AI-technology to assess and interpret patient data across the Unity Network in real time. When a sponsor’s trial protocol is loaded into the platform, patients across the Unity Network can be evaluated and compared against a study’s inclusion and exclusion criteria. This process takes place in real time and VIPER can identify potential patient candidates right as they are diagnosed.
Through Deep Lens’ Real Time Feasibility offering, Precision customers can view the number and de-identified location of current and future eligible patients for specific trials, in real-time. Traditional feasibility testing only provides patient data from a snapshot in time, which is typically reported as best estimates by site research staff. Often, these data are inaccurate and are quickly outdated as new patients are diagnosed or existing patients’ disease evolves or progresses.
VIPER analyzes data from EMRs, pathology, and genomic testing to produce an interactive report dashboard that identifies potential patients who meet a study’s eligibility criteria. Access to this information will help Precision and sponsor project teams to identify specific oncology sites within the Unity Network (United States only) that may have appropriate patients for further investigation and recruitment.
The Real Time Feasibility dashboard provides an at-a-glance view of de-identified results
What countries are served by the Deep Lens Unity Network?
How do I have my clinical trial examined using Deep Lens’ Real Time Feasibility?
What does it cost to have your study initially assessed?
Precision is working constantly to provide cutting-edge solutions to support our sponsor-customers. Access to Deep Lens’ VIPER AI technology and Unity Network is yet another tool to help our sponsors bring life-changing innovations to patients in need.
Learn more about how Precision is providing Next-Gen Oncology CRO services, and how we can accelerate your novel and advanced therapies.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
